Zanamivir

Drug #1734

A neuraminidase inhibitor (antiviral agent), which has been recently approved for the treatment of acute uncomplicated influenza infection, because it reduces replication of influenza A and B viruses. It is most effective for influenza, if started within a few hours of onset of symptoms.

← Previous drug Next drug →

Primary Characteristics

Non-proprietary name: Zanamivir.

Pharmacokinetics

None recorded.

Indications

Zanamivir is primarily indicated in conditions like Acid-related dyspepsia, Influenza.

Contraindications

Zanamivir is contraindicated in conditions like Breast feeding.

Dosage

None recorded.

Drug Interactions

None recorded.

Side Effects

Zanamivir is known to cause more or less tolerable side effects which are usually transient. These include Bronchospasm, GI disturbance, Rashes , Respiratory impairment.

Warnings / Precautions

Zanamivir should be used with caution in patients with asthma and chronic pulmonary disease (risk of bronchospasm----short-acting bronchodilator should be available; avoid in severe asthma unless close monitoring possible and appropriate facilities available to treat bronchospasm); uncontrolled chronic illness; other inhaled drugs should be administered before Zanamivir; pregnancy (use only if potential benefit outweighs risk).

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inhaler

5 mg

Drug Classification

1.6.5.3
2.6.5.3

Manufacturers

Manufacturers of Zanamivir in Pakistan:

GSK